EUVIMEDEUVIMED entdecken
Crossref

Analytical Evaluation of the 2‐in‐1 Adaptive Design for Binary Endpoints

Gosuke Homma iD, Takuma Yoshida iD

Statistics in Medicine · 2026

DOI: 10.1002/sim.70349 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Statistics in Medicine, 2026. Verfasst von Gosuke Homma und 1 weiteren Autor:innen. Beteiligte Einrichtung: Quantitative Sciences & Evidence Generation, Astellas Pharma Inc., Japan. Hauptthemen laut MEDLINE: Endpoint Determination, Research Design. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To reduce drug development costs and time in therapeutic areas with high unmet medical needs, sponsors are often motivated to accelerate the drug development process, specifically by skipping the Phase 2 trial and starting the Phase 3 trial directly after the Phase 1 trial. To address this need, a novel design called 2‐in‐1 adaptive design has been proposed recently. This design allows a trial to maintain a small trial or to expand to a large trial adaptively based on decisions made based on the interim analysis. Although several statistical methods have been proposed for the 2‐in‐1 adaptive design, they specifically emphasize clinical trials with continuous or time‐to‐event endpoints assuming the normal approximation of the test statistic. Methods for the 2‐in‐1 adaptive design with binary endpoints are notably lacking. For binary endpoints, some statistical tests do not rely on the normal approximation. Therefore, it is not clear whether the operating characteristics obtained by existing 2‐in‐1 adaptive design methods in the context of continuous or time‐to‐event endpoints can be generalized to cases with binary endpoints. For this study, we propose formulas to evaluate the type I error rate and power for the 2‐in‐1 adaptive design for binary endpoints. Our proposed formulas can evaluate the exact type I error rate and power without using Monte Carlo simulations. Moreover, the proposed formulas are useful for any statistical test of binary endpoints. Numerical investigations under different scenarios demonstrated that the operating characteristics for the 2‐in‐1 adaptive design with binary endpoints are similar to those with continuous or time‐to‐event endpoints. We present the application of our proposed formulas to a clinical trial in patients with pyruvate kinase deficiency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endpoint DeterminationResearch DesignHumansComputer SimulationModels, StatisticalClinical Trials, Phase I as TopicDrug DevelopmentClinical Trials, Phase II as Topic

Stichwörter der Autor:innen

2‐in‐1 adaptive designbinary endpointexactpowertest sizetype I error rate

Autor:innen und Institutionen

  • Quantitative Sciences & Evidence Generation, Astellas Pharma Inc., Japan.
  • Graduate School of Science and Engineering, Kagoshima University, Japan.

ORCID-Profile: Gosuke Homma, Takuma Yoshida

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Homma, G., & Yoshida, T. (2026). Analytical Evaluation of the 2‐in‐1 Adaptive Design for Binary Endpoints. Statistics in Medicine. https://doi.org/10.1002/sim.70349

Vancouver

Homma G, Yoshida T. Analytical Evaluation of the 2‐in‐1 Adaptive Design for Binary Endpoints. Statistics in Medicine. 2026. doi:10.1002/sim.70349

BibTeX
@article{Homma2026,
  author = {Homma, Gosuke and Yoshida, Takuma},
  title = {Analytical Evaluation of the 2‐in‐1 Adaptive Design for Binary Endpoints},
  journal = {Statistics in Medicine},
  year = {2026},
  doi = {10.1002/sim.70349}
}
Kostenlos starten →